Table 4 Characteristics of patients with IIPs and IPF with or without IgG1-positive cell infiltration.

From: Prognostic implication of IgG4 and IgG1-positive cell infiltration in the lung in patients with idiopathic interstitial pneumonia

 

IgG1-positive IIPs (N = 31)

IgG1-negative IIPs (N = 57)

p-value

IgG1-positive IPF (N = 19)

IgG1-negative IPF (N = 22)

p-value

Age, years

64.0 (20.0–75.0)

66.0 (25.0–78.0)

0.185

66.0 (54.0–74.0)

67.5 (43.0–78.0)

0.838

Sex, male/female

18 (58.1%)/13 (41.9%)

36 (63.2%)/21 (36.8%)

0.639

10 (52.6%)/9 (47.4%)

14 (63.6%)/8 (36.4%)

0.476

Smoking, y/n

6 (42.9%)/16 (51.6%)

33 (57.9%)/24 (42.1%)

0.392

9 (47.4%)/10 (52.6%)

12 (54.5%)/10 (45.5%)

0.647

MDD

IPAF/non-IPAF

10/21

15/42

0.555

5/14

3/19

0.4361

Immunohistochemistry

IgG-positive cell/HPF

74 (10–212)

14 (0–117)

 < 0.001

67 (20–153)

17 (3–117)

 < 0.001

IgG1-positive cell/HPF

49 (32–173)

6 (0–30)

 < 0.001

71 (32–115)

9 (0–30)

 < 0.001

IgG4-positive cell/HPF

5 (0–65)

1 (0–30)

0.004

6 (0–65)

1 (0–75)

0.102

IgG1-positive cell/IgG-positive cell

94.7 (36.2–350.0)

42.3 (0.0–187.5)

 < 0.001

94.7 (36.2–204.5)

51.1 (0.0–187.5)

 < 0.001

IgG4-positive cell/IgG-positive cell

10.0 (0.0–130.0)

5.3 (0.0–85.7)

0.709

11.7 (0.0–42.5)

0.7 (0.0–64.1)

0.131

Laboratory

LDH, U/L

247 (162–361)

223 (132–447)

0.127

247 (193–355)

224 (182–447)

0.380

KL-6, U/mL

1508 (151–16,120)

1175 (221–5646)

0.101

1508 (151–16,120)

976 (348–3030)

0.092

SP-D, ng/mL

293 (74–1350)

195 (45–786)

0.023

365 (74–1350)

155 (69–533)

0.018

serum IgG4, mg/dL

49.0 (8.0–372.0) N = 4

40.5 (9.3–177.0) N = 20

0.122

85.0 (13.0–372.0) N = 3

50.1 (16.3–124.0) N = 6

0.246

Pulmonary function

FVC, L

2.45 (0.71–3.64)

2.46 (1.06–4.62)

0.317

2.28 (0.71–3.31)

2.39 (1.06–3.76)

0.475

%FVC, %predicted

77.4 (30.6–110.4)

79.0 (31.5–126.5)

0.223

74.6 (30.6–110.4)

81.8 (31.5–126.5)

0.506

%DLco, %predicted

59.6 (25.7–124.5)

67.0 (27.7–154.0)

0.598

57.8 (36.2–114.8)

66.7 (27.7–108.0)

0.633

6-min walk test

Distance, m

469 (230–650)

500 (200–660)

0.566

455 (230–650)

450 (200–640)

0.731

min SpO2, %

92 (79–95)

93 (83–96)

0.223

90 (79–95)

93 (88–96)

0.013

GAP index

     

0.703

 Stage I

N.E

N.E

 

10 (71.4%)

14 (77.8%)

 

 Stage II

N.E

N.E

 

4 (28.6%)

4 (22.2%)

 
  1. Data are presented as the median (range) or N (%). Bold font: p-value < 0.05.
  2. DLco diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, GAP gender, age, physiological variable, HPF high-power field, Ig immunoglobulin, IIP idiopathic interstitial pneumonia, IPAF interstitial pneumonia with autoimmune features, IPF idiopathic pulmonary fibrosis, KL-6 Krebs von Lungen-6, LDH lactate dehydrogenase, MDD multidisciplinary discussion, N.E. not evaluable; SP surfactant protein, y/n yes/no.
Back to article page